ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 17 September 15th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on September 29th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; *Voice:* (415) 472-3960; *FAX:* (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

❒ Physician Members

❒ Nurses & Office Managers

❒ Office Staff

❒ Colleagues & Representatives

ADVOCACY

[Editor's Note: ANCO is a member of the *Association of Community Cancer Centers* (ACCC) and a state/regional affiliate of the *American Society of Clinical Oncology* (ASCO). ANCO and the *Medical Oncology Association of Southern California* (MOASC) are members of the *California Medical Association*'s (CMA) *Council on Legislation, House of Delegates*, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO has submitted comments to the *House Ways and Means Health Subcommittee* in response to lawmakers' request for stakeholder input on its *Medicare Red Tape Relief Project*. The *Project* aims to alleviate the regulations and mandates in the Medicare program that impede innovation, increase costs, and prevent the delivery of better care to beneficiaries. Read ASCO's comments at www.asco.org/advocacy-policy/asco-in-action/asco-recommends-steps-reduce-medicare-administrative-burdens.

ASCO confirms that CPT codes 99358 and 99359 (prolonged services without direct patient contact) are payable under the Medicare *Physician Fee Schedule*. These codes are reported when a prolonged, non-face-to-face service is provided to a patient in addition to a face-to-face service. However, these codes may not be reported during the same service period as a complex Chronic Care Management service (CCM) or a Transitional Care Management service (TCM); they can only be used to reported extended qualifying time of the billing physician or other practitioner (not other clinical staff); and, cannot be reported for time spent in non-face-to-face care described by more specific codes having no upper time limit in the CPT code set.

An *Institute for Clinical and Economic Review* (ICER) report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications. Read the report at icer-review.org/material/ovarian-cancer-evidence-report/.

CMS has released its proposed CY2018 *Physician Fee Schedule* (PFS) and *Outpatient Prospective Payment System* (OPPS) rules. Read the proposed rule at www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment; read the fact sheet at www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html. Major changes include a reduction in payments to hospitals participating in 340B under OPPS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell's summary of the proposed rule at www.anco-online.org/BBMPFS2018Analysis.pdf. Read ASH's comments on the proposed rules at www.hematology.org/Advocacy/Testimony.aspx/. Read ACCC's comments on the proposed OPPS and PFS rules at www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-OPPS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=5oSB4 and www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-PFS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=6oSB4, respectively.

The *Medicare Quality Payment Program* (QPP), established by the *Medicare Access and CHIP Reauthorization Act* (MACRA), began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control

over the availability of certified EHR technology. Learn more at qpp.cms.gov/about/hardship-exception.

CMS has issued a proposed rule that would make changes in the second year of the QPP. The proposed rule "aims to simplify the program, especially for small, independent, and rural practices." Read the CMS fact sheet at qpp.cms.gov/docs/QPP_Proposed_Rule_for_QPP_Year_2.pdf; and, read Bobbi Buell's analysis at www.anco-online.org/BBMIPS2018.pdf. ASCO submitted comments to CMS on the proposed rule arguing that its data show that the median financial penalty for oncology practices under the proposal would range from 14-23%, well beyond the CMS-envisioned 4% penalty. ASCO urged CMS to refrain from implementing such a policy at any point in time. In addition, ASCO urged CMS to implement multiple oncology-focused APMs, including its own PCOP model. Read ASCO's comments at www.asco.org/sites/new-www.asco.org/files/content-files/QPP-2018-Proposed-Rule-Comments.pdf; read ASH's comments at www.hematology.org/Advocacy/Testimony.aspx; read ACCC's comments at accc-cancer.org/ACCCbuzz/accc-comments-to-cms-on-quality-payment-program-proposed-rule/?utm_source=ACCConnect&utm_medium=email&utm_campaign=ACCConnect091317&_zs=bhddd1&_zl=8oSB4.

CMS invites representatives from organizations of all sizes to assess current and future functionality of the *Quality Payment Program* website (qpp.cms.gov) as well as make recommendations for improvements. If interested, then e-mail partnership@cms.hhs.gov to participate in a one-on-one feedback session.

Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS *Quality Payment Program* website to determine if they should participate in MIPS. Visit qpp.cms.gov > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to qpp.cms.gov and select "Subscribe to Email Updates" at the bottom of the page.

ASCO is pleased to announce that its *Quality Oncology Practice Initiative* (QOPI) *Qualified Clinical Data Registry* (QCDR) is now available for CMS MIPS reporting effective July 1st. By using the QOPI QCDR for MIPS reporting, practices will be able to report on one measure for one patient in 2017 to avoid cuts to Medicare reimbursements in 2019. Express your interest in participating in the QOPI QCDR by e-mailing qopi@asoc.org. Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting. Registration closes October 1st.

ASCO's series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. **ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status** at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra. ASH's updated MACRA webpage is at www.hematology.org/Clinicians/7427.aspx. **ASH members can now sign up to report data for the Medicare MIPS through *Healthmonix's* MIPSPRO, a 2017 Qualified MIPS Registry**. Learn more at healthmonix.com/mips-pro/.

The *American Medical Association* (AMA) has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting*. The video and other AMA resources are available at www.ama-assn.org/qpp-reporting. **CMA's *Center for Economic Services* (CES) has published an update to its MACRA preparation checklist** entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra.

CMA, MOASC, and State Legislative & Regulatory Issues

Forthcoming CMA webinars include:

- MACRA: Guidance on Merit-Based Inventive Payment System (MIPS; September 20)
- Assembly Bill 72: How to Challenge the Interim Payment of Out-of-Network Services at In-Network Facilities (September 27)

Contact CMA's member help center at (800) 786-4262 or memberservice@cmanet.org for more information. Register online at www.cmanet.org/events.

CMA Practice Resources* (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The September 2017 edition includes:

- Physicians report Anthem not complying with AB72 interim payment rules
- Updates to prior authorization form for prescription medications and new timelines for response now in effect
- Noridian reports spike in provider deactivations and lost revenue
- Anthem Blue Cross offering fall seminars on 2017 operational updates
- The Coding Corner: Proper coding for bilateral procedures

Noridian/JEMAC, DHCS/MediCal, & Private Payers

***Noridian Administrative Services* is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC).** Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews
  Announcements—Hospice Compare Update Document Available; Participate in Quality Payment Program Website Testing; Billing for Stem Cell Transplants; Hospice Provider Preview Reports Available through September 28; Quality Payment Program: New Resources Available
  Claims, Pricers, and Codes—October 2017 Average Sales Price Files Available
  Events—Qualified Medicare Beneficiary Program Billing Requirements Call-September 19; Reporting Hospice Quality Data: Tips for Compliance Call-September 20; PQRS: Feedback Reports and Informal Review Process for PY2016 Results Call-September 26; Physician Compare Call-September 28
  Publications—Medicare Costs at a Glance: 2017 Educational Tool-Reminder; Physician Fee Schedule Fact Sheet-Reminder; Telehealth Services Fact Sheet-Reminder; Transitional Care Management Services Fact Sheet-Reminder; Medicare Home Health Benefit Booklet-Reminder; Medicare Enrollment Resources Educational Tool-Reminder

- September Webinars-Register Now
- HPTCs Code Set-October 2017 Update CR10141
- Claim Status Category and Claim Status Codes Update CR10132
- MolDX: NSD1 Gene Tests; Myriad BRCAnalysis CDx; PIK3CA Gene Tests; RPS19 Gene Tests; TERC Gene Tests; IKBKAP Genetic Testing-Billing and Coding Guidelines
- MIPS and APM Webpage Available To Help with the October 1, 2017 Deadline
- MPFSDB October 2017 Quarterly Update CR10222
- Screening for Lung Cancer with LDCT-Second Revision-Republished CR9246
- CMS-1500 Claim Form Must Be the 02/12 Version
- MolDX: ResponseDX Tissue of Origin R2
- MolDX: Percepta Bronchial Genomic Classifier LCD-R1
- MolDX: APC and MUTYH Gene Testing LCD-R1
- Intensity Modulated Radiation Therapy (IMRT) LCD-R4

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- Modifier 59 Clarification and Changes Webinar (September 19)
- Basic E and M Avoiding Common Errors Webinar (September 20)
- Recoupment Overpayment Timeline and Payment Options Webinar (September 21)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

UnitedHealthcare's Network Bulletin (August 2017) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles about the new care provider website (UHCprovider.com), the new PreCheck MyScript app, and how to improve patient engagement.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017 Professional Education Meeting

ANCO hosted its 2017 professional education meeting on September 6th at the *San José Fairmont*. The agenda included *QPP/MACRA, ASCO's COME HOME Project, USP797/800,* and *California Legislative/Regulatory Updates*. Download the presentations at www.anco-online.org/education.html.

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The second *Update* took place on September 9th at the *Stanford Park Hotel* with Bruno Medeiros, M.D., *Stanford University,* Charalambos Andreadis, M.D., *University of California, San Francisco,* and Brian Sworder, M.D., *Stanford University*. The latest research on novel treatment modalities for leukemias and lymphomas, along with case studies for these diagnoses was presented. These updates are supported by *Janssen Biotech, Merck, Pfizer Oncology,* and *Pharmacyclics*. Download the presentations at www.anco-online.org/education.html.

SAVE THE DATE
18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute, UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org to register your interest in receiving registration and housing information when it becomes available in the Fall.

Additional Education Meetings

September 24-27th
59th Annual Meeting
ASTRO
San Diego
(www.astro.org)

September 26th
Highlights from the 2017 ASCO Annual Meeting (Part I of Your Guide to the Latest Cancer Research and Treatment
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 27-28th
ASCO Advocacy Summit 2017: Lead, Engage, Influence
ASCO
Alexandria
(www.surveymonkey.com/r/AdvocacySummit2017)

September 28th
Highlights from the 2017 ASCO Annual Meeting (Part II of Your Guide to the Latest Cancer Research and Treatment
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 2nd
Treatment Update on Liver Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 4th
What's New in the Treatment of Waldenstrom's Macroglobulinemia (WM)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 5th
Progress in the Treatment of Indolent Non-Hodgkin Lymphoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 6th
Update on Soft Tissue Sarcoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 6-7th
12th Annual Congress: Hematologic Malignancies
NCCN
San Francisco
(www.nccn.org/professionals/meetings/hematological/default.aspx)

October 18-20th
34th National Oncology Conference
ACCC
Nashville
(www.accc-cancer.org/meetings/NOC2017.asp)

October 19th
Living with Metastatic Breast Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Individual Member News

ANCO is pleased to announce that Daniel P. Mirda, M.D., *ANCO President,* has been chosen as one of ASCO's Advocacy Champions based on his advocacy efforts in 2016.

The *Conquer Cancer Foundation* (CCF) of the *American Society of Clinical Oncology* (ASCO) is now accepting applications for the 2018 *Young Investigator Award* (YIA). The *Association of Northern California Oncologists* (ANCO) is funding one 2018 YIA for a qualified northern California applicant, and urges all eligible northern California physicians to apply. The YIA is a one-year, $50,000 grant that provides research funding to promising physicians to support their transition from final years of training to faculty appointment and to encourage and promote quality research in clinical oncology. Applications in all areas of cancer research are accepted from U.S. and international applicants. For 2018, CCF has dedicated funding for the following areas: breast cancer, northern California researchers, global oncology, kidney cancer, lung cancer, pediatric cancer, sarcoma, and supportive care. Other areas of interest include cholangiocarcinoma, chronic lymphocytic leukemia, gynecological cancers, and melanoma. YIA applications opened on July 1st and are due by 11:50PM ET on September 21st. Eligibility criteria, award details, and the request for proposals are available on the CCF website (www.conquer.org/young-investigator-award). For questions about the YIA or assistance with your application, please e-mail grants@conquer.org.

ASCO urges community oncologists to join ASCO's *Leadership Development Program*. Participants in this year-long leadership program will gain extensive exposure to the roles and mission of ASCO, its leadership, and the *Society's* powerful place in developing the future of cancer care. Visit www.asco.org/training-education/professional-development/leadership-development-program for more information and to apply before September 25th.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care,* and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

The *UCSF Stephen and Nancy Grand Multiple Myeloma Initiative* invites ANCO members to join them at their annual retreat on October 2nd on the UCSF Mission Bay Campus. For more information, contact Cammie Edwards, *Program Director, Grant MMTI* at cammie.edwards@ucsf.edu

The *Stanford Cancer Center's MDS Center* is co-sponsoring a the MDS Foundation's Educational Patient-Caregiver Forum on Saturday, October 28. The Forum takes place at 875 Blake Wilbur Drive, Room 2103, Stanford, CA 94305 from 9:30AM through 2PM.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with

substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics
Taiho Oncology • Takeda Oncology • Tesaro
TEVA Oncology

We especially wish to thank and welcome *Agendia, bioTheranostics, EMD Serono, Kite Pharmaceuticals, Pfizer US Biosimilars,* and *Puma Biotechnology* as new Corporate Members for 2017. *Dendreon, Genoptix Medical Laboratory, GenPath Oncology, Infinity Pharmaceuticals, Ipsen Biopharmaceuticals. Medivation, Merrimack Pharmaceuticals,* and *Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AMGEN informs ANCO that the *United States Food and Drug Administration* has approved Mvasi as a biosimilar to Avastin. Mvasi is the first biosimilar approved in the United States for the treatment of cancer. It is appoved for the treatment of metastatic colorectal cancer (in combination with 5-fluorouracil-based chemotherapy for first- or second-line treatment; in combination with flouropyrimidine-irinotecan or flouropyrimidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line bevacizumab product-containing regimen), non-squamous non-small cell lung cancer (in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease), glioblastoma (with progressive disease following prior therapy, based on improvement in objective response rate), metastatic renal cell carcinoma (in combination with interferon alfa), and cervical cancer (that is persistent, recurrent, or metastatic disease, in combination with paclitaxel and cisplatin or paclitaxel and toptecan).

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved Faslodex for initial mono therapy for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor negative (HER2-) advanced breast cancer not previously treated with endocrine therapy.

Bayer Healthcare Pharmaceuticals informs ANCO that the *United States Food and Drugs Administration* has approved Aliqopa for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

Celgene informs ANCO that the *United States Food and Drugs Administration* has approved Idhifa for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with in isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Genentech BioOncology informs ANCO that the *United States Food and Drug Administration* has approved Actemra for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in people two years of age or older.

Genentech BioOncology is hosting an educational dinner program in Sacramento on September 22nd at 6PM entitled *Tecentriq: Cancer Immunotherapy in Previously Treated Metastatic Non-small Cell Lung Cancer*. To register, visit www.medforcereg.com/SGEN8189.

Genomic Health informs ANCO that *Anthem* has a new prior authorization process for Oncotype DX. Effective July 1st, *Anthem's* AIM subsidiary will perform prior authorizations (PAs) for all genomic tests. Under the new rules:

- The oncology office is required to initiate the PA.
- The PA process must be started online at the AIM portal for ALL patients as this is the ONLY way to know which patients can be completed online.
- The practice must be registered on the AIM portal before attempting to do a PA. (Register on AIM's portal at www.providerportal.com.)

Currently only certain *Anthem* patients (those that are "fully-insured") can have PAs completed online. The portal will indicate, once the patient's insurance information is entered, if the PA process can be completed online or if the old system must be used. As of January 1st, 2018, PAs will be completed on the portal for all patients. Complete the PA online if the portal so indicates and then either 1) FAX the approval PA number you are given to *Genomic Health* at (866) 383-1932, or 2) upload the approval to *Genomic Health's* physician portal. If you are not allowed to complete the PA on the AIM portal, you must either complete the PA on *Genomic Health's* physician portal, or use the paper form and FAX to *Genomic Health* at the above number. For Medicare Advantage patients you do not currently need to use the AIM portal as described above. Instead, complete as usual the *Anthem* PA on *Genomic Health's* physician portal and submit PA approval with your Oncotype order either by FAX (866-383-1932) or upload on *Genomic Health's* portal. However, effective November 1st, you will need to use the AIM for your Medicare Advantage patients. Please contact Jack Spicer, MD, *Medical Director, Managed Care Medical Affairs, Genomic Health,* at jspicer@genomichealth.com if you have any questions.

Merck informs ANCO that the *United States Food and Drug Administration* has issued a statement about the risks associated with the use of Keytruda in combination with dexamethasone and an immumomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. The statement is based on review of data from two clinical trials (Keynote-183 and Keynote-185). The statement does not apply to patients taking Keytruda for an approved indication. Keytruda is not approved for treatment of multiple myeloma..

Novartis Oncology informs ANCO that the *United States Food and Drug Administration* has approved Kymriah for children and young adults with B-cell acute lymphoblastic leukemia.

Pfizer Oncology informs ANCO that the *United States Food and Drug Administration* has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor actue lymphoblastic leukemia (ALL).

Pfizer Oncology informs ANCO that the *United States Food and Drug Administration* has approved Mylotarg for the treatment of newly-diagnosed CD33-positive actute myeloid leukemia (AML) in adults and for the treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older. Mylotarg may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML, or as a stand-alone treatment for certain adult and pediatric patients.

Puma Biotechnology informs ANCO that the *United States Food and Drug Administration* has approved Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer.

Clinical Trial News

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

• A Phase II Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma (SARCOMA0029; NCT01755195]. Principal Investigator: Kristen Ganjoo, MD; Contact: Maria Ahern, (650) 725-6413, mahern@stanford.edu.

• A Randomized Phase 3 Trial of TRC-105 and Pazopanib Versus Pazopanib Alone in Patiens with Advanced Angiosarcoma (TAPPAS) (SARCOMA0027; NCT02979899]. Principal Investigator: Kristen Ganjoo, MD; Contact: Maria Ahern, (650) 725-6413, mahern@stanford.edu.

• 68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients with Intermediate and High-Risk Prostate Cancer (PROS0077; NCT03113617]. Principal Investigator: Andrei Iagaru, MD; Contact: Jordn Cisneros, (650) 725-6409, jordan.cisneros@stanford.edu.

• Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma (AGE RANGE: 5 to 21 Years) (PBTC048; NCT03033992]. Principal Investigator: Paul Fisher, MD; Contact: Leah White, (650) 725-4708, lwhite15@stanford.edu.

• Phase II Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors (AGE RANGE: 2 Years to 30 Years) (COCADVL1622; NCT02867592]. Principal Investigator: Sheri Spunt, MD; Contact: Christina Baggott, (650) 497-7659, baggott@stanford.edu.

• A Phase I/II Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors (AGE RANGE: 1 Month to 21 Years) (PEDSVAR0044; NCT02637687]. Principal Investigator: Sheri Spunt, MD; Contact: Nancy Sweeters, (650) 721-4074, nancy.sweeters@stanford.edu.

• Feasibility Study of New Method of Diagnostic and Prediction of Painful Chemotherapy Induced Neuropathic Pain (CIPN) (GYN0006; NCT03206216]. Principal Investigator: Oliver Dorigo, MD; Contact: Mark Santos, (650) 498-5189, mark.santos@stanford.edu.

• A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL) (CCT5006-EXP; NCT03153462]. Principal Investigator: David Miklos, MD; Contact: Julianna Craig, (650) 725-8130, jkcraig@stanford.edu.

• Open-Label, Phase II Study of Anti-programmed Death-Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination with Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma (ECOG-ACRIN-PRE0505; NCT02899195]. Principal Investigator: Joel Neal, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu.

• A Phase III Randomized Study of Nivolumab plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) (ECOGS1400: S1400I; NCT02785952]. Principal Investigator: Heather Wakelee, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu.

• Randomized, Double-Blind Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed by Nivolumab/Placebo for Locally Advanced Non-Small Cell Lung Cancer (LUN0087; NCT02768558]. Principal Investigator: Maximilian Diehn, MD; Contact: Madelyn Kissel, (650) 497-8966, mkissel@stanford.edu.

• Elastography in Thyroid Nodule Evaluation (END0020; NCT03174925]. Principal Investigator: Aya Kamaya, MD; Contact: Divya Pathak, (650) 721-0004, divya22@stanford.edu.

• A Pilot Study of Dabrafenib and Trametinib for Patients with BRAF Mutated Ameloblastoma (ENT0043; NCT02367859]. Principal Investigator: A Dimitrios Colevas, MD; Contact: Stefania Chirita, (650) 723-1423, schirita@stanford.edu.

• A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosamide, and Cisplatin (TIP) with High-Dose Chemotherapy using Mobilizing Paclitaxel Plus Ifosamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory

Germ Cell Tumors (ECOG-ACRIN-A031102; NCT02375204]. Principal Investigator: Sandi Srinivas, MD; Contact: Caitlin Plahn, (650) 723-3046, cplahn@stanford.edu.

• A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (SARCOMA0026; NCT03016819]. Principal Investigator: Shivaani Kummar, MD; Contact: Feriel Buchholz, (650) 721-4090, ferielbu@stanford.edu.

• A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression (VAR0150; NCT03125200]. Principal Investigator: Shivaani Kummar, MD; Contact: Jee Min Lee, (650) 721-4084, jeelee@stanford.edu; Feriel Buchholz, (650) 721-4090, ferielbu@stanford.edu.

• A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors (VAR0129; NCT02428712]. Principal Investigator: Shivaani Kummar, MD; Contact: Jee Min Lee, (650) 721-4084, jeelee@stanford.edu.

• Efficacy and Safety of LifeSeal Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study (REC0009; NCT02907385]. Principal Investigator: Andrew Shelton, MD; Contact: Nicholas Oberhelman, (650) 724-3866, noberhel@stanford.edu.

• A Multicenter, Open-label, Phase II Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease (BRSMTS0026; NCT02981303]. Principal Investigator: Melinda Telli, MD; Contact: Sumita Sood, (650) 723-0618, ssood@stanford.edu.

• Analysis of Skin Perfusion Changes in Two Staged Nipple-Sparing Mastectomies Using the Spy Elite Imaging System (BRS0065]. Principal Investigator: Irene Wapnir, MD; Contact: Shannon Meyer, (650) 724-1953, smeyer27@stanford.edu.

• A Phase Ib/II Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer (VAR0149; NCT02953782]. Principal Investigator: George Fisher, MD; Contact: Flordeliza Mendoza, (650) 724-2056, flormend@stanford.edu.

Further information is available at cancer.stanford.edu/trials/.

UC Davis brings the following clinical trials (not previously listed or changed) to the attention of the ANCO membership:

• A Pilot Study of Intralesional IL-2 and Hypofractionated Radiotherapy in Patients with Metastatic Non-Small Cell Lung Cancer Who Are Refractory to PD-1/PD-L1 Blockade (UCDCC#269/NCT03224871). Principal Investigator: Arta Monjazeb, M.D.; Contact: Heather Melanson, (916) 734-8628

Further information is available at www.ucdmc.ucdavis.edu/cancer/clinical_trials/.

UC San Francisco's malignant hematology and stem cell transplant clinical protocols are available at www.anco-online.org/UCSFMaligHemeClinicalTrials2017.pdf.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

• A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations (CC#169514). Contact: Ann Chan, (415) 885-3670, ann.chan@ucsf.edu

• Expanded Access Protocol for Therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in Patients with Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy (CC#16455). Contact: Bryant Chee, (415) 353-7145, bryant.chee@ucsf.edu

• Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors (CC#16954). Contact: Denisha Otis, (415) 748-9513; denisha.otis@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to apps.asco.org/oncology-practice-central/survey.

ASCO has issued a guideline on clinician-patient communication outlining best practices on how cancer clinicians communicate with patients with the goal of enhancing the oncology provider-patient relationship. Read the guideline at www.asco.org/practice-guidelines/quality-guidelines/guidelines/supportive-care-and-treatment-related-issues#/27581.

The September 2017 issue of ASCO's *Journal of Oncology Practice* (JOP) is available online and features articles entitled *The TEAM Approach to Improving Oncology Outcomes by Incorporating Palliative Care in Practice; What Enables Oncologists to Discuss Goals of Care With Their Patients? Practical Ways Toward a Culture of Kindness, Transparency, and Responsibility; Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic; Opioids in Cancer Pain: Right or Privilege.* Visit jop.ascopubs.org for more information.

ASCO and *Innovative Oncology Business Solutions* (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

The September/October issue of ACCC's *Oncology Issues* includes articles entitled *The Role of the Oral Oncology Nurse Navigator; Painting a Brighter World in Cancer Care;* and, *Best of ASCO 2017.* Visit www.accc-cancer.org/oncology_issues to read this issue.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria,* and/or *Radiation Therapy Compendium* for acute lymphoblastic leukemia (V3.2017); B-cell lymphomas (V4.2017); bladder cancer (V5.2017, final version); bone cancer (V1.2018); cervical cancer (V1.2017, radiation recommendations); CLL/SLL (V1.2018, radiation recommendations); distress management (V2.2017); kidney cancer (V1.2018, chemotherapy templates, radiation recommendations); myelodysplastic syndromes (V1.2018); myeloproliferative neoplasms (V2.2018); ovarian cancer (V3.2017); pancreatic adenocarcinoma (V3.2017); systemic light chain amyloidosis (V1.2018); uterine neoplasms-endometrial carcinoma (V2.2017, final version); uterine neoplasms (V3.2017, radiation recommendations); vulvar cancer (V1.2017, radiation recommendations). Go to www.nccn.org for more information.

NCCN is collaborating with Evinance to integrate NCCN *Clinical Practice Guidelines in Oncology* into the *Evinance Decision Support Platform* to allow for point-of-care access to treatment recommendations derived from the NCNC *Guidelines*. Learn more at www.nccn.org/about/news/newsinfo.aspx?NewsID=970.